{"id":"veracept","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypokalemia"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This inhibition leads to a decrease in the conversion of cortisone to cortisol, resulting in a reduction of cortisol levels in the body. This can be beneficial for patients with conditions such as Cushing's syndrome or congenital adrenal hyperplasia.","oneSentence":"VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:27.608Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Congenital adrenal hyperplasia"},{"name":"Cushing's syndrome"}]},"trialDetails":[{"nctId":"NCT02446821","phase":"PHASE2","title":"Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception","status":"COMPLETED","sponsor":"Sebela Women's Health Inc.","startDate":"2015-06","conditions":"Contraception","enrollment":286},{"nctId":"NCT03633799","phase":"PHASE3","title":"Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sebela Women's Health Inc.","startDate":"2018-08-22","conditions":"Women at Risk for Pregnancy","enrollment":1620},{"nctId":"NCT03785366","phase":"PHASE3","title":"A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)","status":"COMPLETED","sponsor":"Sebela Women's Health Inc.","startDate":"2018-12-17","conditions":"Women at Risk for Pregnancy","enrollment":41},{"nctId":"NCT02167763","phase":"PHASE1","title":"Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD","status":"COMPLETED","sponsor":"Sebela Women's Health Inc.","startDate":"2013-11","conditions":"Prevention of Pregnancy","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VeraCept","genericName":"VeraCept","companyName":"Sebela Women's Health Inc.","companyId":"sebela-women-s-health-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Used for Congenital adrenal hyperplasia, Cushing's syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}